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Molecular docking of 1 to 51 compounds has been performed in Small-Molecule Drug Discovery Suite of Schrödinger. 
Fifty one compounds have been targeted on 2NSD and 2X22 involved in tuberculosis activity. Aryloxy moiety on refluxing 
with chloroethyl acetate in the presence of potassium carbonate and acetone has yielded ethyl aryloxy acetate  (A), which 
have been reacted with hydrazine hydrate to produce aryloxyacetyl hydrazine  (B), which on treatment with aromatic 
aldehydes or ketones yield hydrazones  (C). The novel series of compounds have been elucidated on the basis of spectral 
studies and screened for antimycobacterial activity. The compounds are significantly sensitive at concentration 50 and  
100 μg/mL. Compound 11 shows sensitivity at 25 μg/mL. The antibacterial activity is strongly connected with the position 
of the substituent on aromatic aldehyde or ketones in relation to the hydrazide skeleton. 
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In hydrazone, the nitrogen is attached to hydrogen; 
these Hydrazone are stable enough for isolation1. 
However in some cases, especially with simple R 
group, they rapidly decompose or polymerizes unless 
there is at least one aryl group on nitrogen or the 
carbon2. When there is an aryl group the compound 
are quite stable and these compound called as Schiff  
bases and the reaction is best way to prepare them. 
The reaction is straightforward and proceeds in high 
yield3. 
Tuberculosis (TB) is a deadly disease caused by 
mycobacterium of the “tuberculosis complex”, 
including primarily Mycobacterium tuberculosis as 
well as Mycobacterium bovis and Mycobacterium 
africanum4. 
Drug discovery and development could be a 
complicated, time intense and a rich method5. It 
becomes still more expensive when the safety, 
efficacy and other issues are raised. In silicoapproach 
of drug design, computational approach plays a 
significant role in all stages of drug development from 
the initial lead design to final stage clinical 
development6. 
M. tuberculosis contains mycolic acids that are 
unusually long chain α-alkyl β-hydroxy fatty acids of 
60–90 carbons7. The antitubercular (anti-TB) drugs 
such as isoniazid8 and ethionamide9 have shown to 
target the synthesis of these mycolic acids, which are 
the central constituents of mycobacterial cell wall. 
The chemistry of these derivatives has been the 
fascinating field of investigation in medicinal 
chemistry, they have been found to exhibit enhanced 
biological profile. Hydrazone are known to exhibit 
wide variety of biological activities. They are used as 
antibacterial agent, anti-tubercular agents, analgesic, 
anti-inflammatory agent, antiviral agents, antifungal 
agent, muscle relaxants and antihistamines, etc10-13. 
The enzymatic acetylation of isoniazid by N-
acetyltransferase (NAT) represents a major metabolic 
pathway for isoniazid in humans, so blocking 
acetylation via chemical modification of the 
hydrazine unit with a functional group, while 
preserving potent antimycobacterial action, has the 
potential to counterbalance the known side effects of 
INH, improve clinical outcomes and reduce the 
emergence of acquired isoniazid resistance in patients. 
Subsequently, numerous studies have pointed out the 
importance of developing novel hydrazones as 
promising anti-tubercular agents. 
 
Materials and Methods 
 
Molecular Docking 
All fifty one compounds (Table I) were docked in 
Small-Molecule Drug Discovery Suite of 
Schrödinger. All these compounds were targeted on 
seven enzymes such as 2NSD and 2X22 involved in 
tuberculosis activity. The generated lower energy 
conformers of all ligands were docked into generated 
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grid of active site of enzymes by XP precision of 
docking inside Glide-v7.4 14, 15. 
 
Synthesis 
The reactions were carried out in oven-dried 
glassware (120°C) under an atmospheric condition 
unless as indicated otherwise. Chemicals and related 
solvents were of Merck Chemicals Co and purchased 
from Gurudatta Chemical Distributor, Satara. 
Analytical thin layer chromatography (TLC) was 
performed on percolated plates and purifications were  
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Table I — List of compounds screening for molecular docking (Contd.) 
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Table I — List of compounds screening for molecular docking (Contd.) 
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Table I — List of compounds screening for molecular docking (Contd.) 
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Scheme I 
 
 
done for all ten synthesized compound by column 
chromatography. 
The physical data such as melting points were 
determined in open capillary tubes. IR spectra were 
recorded on Shimadzu, MIRacle-10, IRAffinity-1,  
H NMR spectra on Agilent, VNMRS 400 using 
CDCl3 solvent and mass spectra on Agilent, 6103 
quadrapole LCMS.  
Ethyl aryloxy acetate (A): A mixture of eugenol 
(0.1 mol), ethyl chloro acetate (0.1 mol) and 
anhydrous potassium carbonate (0.15 mol) in dried 
acetone was refluxed for 12 h. Resultant mixture was 
distilled off and poured on to ice-cold water and 
stirred. Residue was extracted with ether and the 
extract was dried over anhydrous sodium sulphate and 
was purified under reduced pressure to yield 
compound A. 
Ethylaryloxy acetyl hydrazine (B): A mixture of 
compound A (0.05 mol) and hydrazine hydrate (0.075 
mol) in ethanol was refluxed for 4 h and after 
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distilling off the solvent the residue was recrystallized 
from methanol to yield compound B. 
Hydrazone (C): A mixture of compound B (0.01 
mol) and aromatic aldehyde  (0.01 mol) or ketone was 
refluxed for 2h using acetic acid. Crystals formed 
were washed with ice-cold water, dried and 
recrystallized from methanol to yield compound 
(Scheme I) 
 
Anti-tubercular activity 
The synthesized compounds were evaluated for 
anti-tubercular activity against standard strain 
H37RV. The method used was microplateAlamar 
Blue assay (MABA). Being a non-toxic method, it has 
several advantages such as thermal stability of the 
reagent, and good correlation with BACTEC 
radiometric method. The final drug concentrations 
tested were 100 to 0.2 µg/mL. Plates were covered 
and sealed with parafilm and incubated at 37ºC for 
five days. After addition of Alamar Blue reagent and 
incubating for 24 hrs, the results were observed. A 
blue color in the well was interpreted as no bacterial 
growth, and pink color was scored as growth.  
Results and Discussion 
 
Molecular docking 
The Insilco study of all fifty one compounds was 
performed in Small-Molecule Drug Discovery Suite of 
Schrödinger. The compounds 4, 5, 11, 18, 30, 34, 35, 
37, 38, 42, 43, 44, 45, 46 and 47 having good docking 
score and predicted interaction with enzymes. The 
docking result of novel hydrazone demonstrated that 
the binding energies were in therange of -6.097 
kcal/molto -10.393 kcal/mol, with the minimum 
binding energy of -10.393kcal/mol (Table II). The 
 
Table II — Docking score of compounds 
Title XP GScore Title XP GScore Title XP GScore Title XP GScore 
2NSD 2X22 
Isoniazide -3.682      Isoniazide -5.451   
1 -8.747 27 -7.37 1 -5.959 27 -- 
2 -6.847 28 -8.101 2 -4.009 28 -7.486 
3 -- 29 -6.097 3 -8.007 29 -2.37 
4 -10.393 30 -9.021 4 -8.426 30 -7.769 
5 -7.919 31 -7.804 5 -6.09 31 -6.092 
6 -7.247 32 -6.384 6 -- 32 -4.919 
7 -7.179 33 -6.955 7 -6.67 33 -6.071 
8 -8.387 34 -10.13 8 -5.981 34 -7.448 
9 -8.525 35 -9.813 9 -7.538 35 -- 
10 -7.099 36 -6.538 10 -- 36 -6.226 
11 -9.5 37 -9.632 11 -7.726 37 -9.092 
12 -6.942 38 -9.587 12 -4.965 38 -7.932 
13 -8.921 39 -6.818 13 -- 39 -5.289 
14 -8.216 40 -6.921 14 -8.073 40 -7.674 
15 -7.428 41 -6.98 15 -6.721 41 -- 
16 -7.815 42 -9.747 16 -2.124 42 -8.527 
17 -7.266 43 -9.256 17 -6.04 43 -6.551 
18 -7.632 44 -8.898 18 -6.625 44 -5.356 
19 -7.681 45 -9.049 19 -5.954 45 -6.262 
20 -7.466 46 -9.593 20 -4.423 46 -7.758 
21 -6.799 47 -9.485 21 -7.037 47 -7.556 
22 -7.005 48 -6.469 22 -5.353 48 -4.896 
23 -7.867 49 -8.072 23 -- 49 -5.725 
24 -7.883 50 -6.338 24 -4.742 50 -6.666 
25 -8.657 51 -6.175 25 -6.098 51 -4.293 
26 -8.15   26 -4.74   
Note-: Sign ‘ -- ’ indicate compound does not show any Gscore. 
 
 
 
 
Figure 1 — Orientation of compound 4 with 2NSD enzyme 
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molecules were then tested for structure analysis by the 
visualization tool. The entire compounds protein-ligand 
complex showed H - bond with the active site residue 
TYR 158 and PHE 149 (Figure 1). 
 
Synthesis 
Ten hydrazone derivatives compound no. 4, 5,  
11, 18, 30, 34, 35, 37, 42 and 45were selected  
 
on the basis of their in silico results.  
The derivatives were synthesis by condensation of 
arylhydrazide with various aromatic aldehyde or 
ketone using ethanol. Physical data of all  
synthesized compounds are shown in Table III  
and characterization data mentioned in  
Table IV. 
 
 
Table III — Physical characteristics of synthesized compounds 
Compd Ar’ Mol. Formula Mol. 
Weight 
m.p. 
(°C) 
Yield 
(%) 
4 
OH
OH  
C21H24N2O5 384.19 220-221 73.08 
5 
I
I  
C19H18I2N2O3 576.18 235-236 62.00 
11 
NH2
 
C21H25N3O3 367.44 191-192 72.03 
18 
OH
 
C19H20N2O4 340.37 229-230 75.00 
30 
NH2
 
C21H25N3O3 367.44 190-191 59.15 
     (Contd.) 
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Table III — Physical characteristics of synthesized compounds (Contd.) 
Compd Ar’ Mol. Formula Mol. 
Weight 
m.p. 
(°C) 
Yield 
(%) 
34 
OH
 
C21H24N2O4 368.43 217-218 74.08 
35 
NO2
 
C21H23N3O5 397.42 235-236 60.08 
37 
NH2
 
C21H25N3O3 367.44 190-191 72.03 
42 
OH
 
C21H24N2O4 368.43 219-220 76.90 
45 
 
C21H24N2O3 352.43 184-185 65.55 
 
 
In the IR spectra, all derivatives of hydrazone had 
a characteristic band inthe region 1700-1650 cm−1 
due to the C=O stretching vibration. The N-H 
stretchingvibration of the compounds found a band 
at 3400-3150 cm−1. Thestretching bands for C=C and 
C=N groups were observed at 1610-1490 cm−1. 
Ingeneral the IR stretching frequencies for –OH 
groups varied for the compounds 4, 18, 34 and  
42 inthe region 3200-3650 cm−1.In the 1H NMR 
spectra of all the compounds, the aromatic 
andaliphatic protons were observed at the expected 
ppm scale. Aromatic protons wereobserved at  
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about δ 6.15-7.78. Because hydrazoneshas some 
characteristic peak such as –OH, -N-H, -CH=N-N 
protons were observed as couples of peaks at  
δ 4.90-5.10, δ 7.10-6.90, δ 3.35-2.53 respectively. 
Antimycobacterial activity 
The compounds were evaluated in vitro for 
antimycobacterial activity against M. tuberculosis 
H37Rv using microplatealamar blue assay (MABA) 
 
Table IV — IR, 1H NMR and Mass data of synthesized compounds 
Compd 
-C No. 
IR, 1H NMR and Mass data 
4 
IR: 3288, 2945, 1653 for CO of CONH, 1568, 1506, 1352, 1273, 1213, 1157, 840, 561 cm−1; 1H NMR  (400 MHz, DMSO-d6): 
δ 3.75  (t, CH3), 6.40  (s, CH), 3.20  (d, CH2), 6.51  (s, CH), 6.54  (s, CH), 4.21  (d, CH2), 3.07  (d, CH2), 8.1  (s, NH), 8.6  (s, 
N=CH), 3.0  (s, CH), 1.2  (t, CH3), 6.78  (s, CH), 6.24  (s, CH), 6.15  (s, CH), 5.1  (s, OH), 4.9  (s, OH), 6.34  (s, H); MS: m/z
384.1 
5 
IR: 3660, 2943, 2806, 1674 for CO of CONH, 1595, 1544, 1273, 1041, 842, 758, 636, 574 cm−1; 1H NMR  (400 MHz, DMSO-
d6): δ 3.73  (t, CH3), 6.40  (s, CH), 3.20  (d, CH2), 6.51  (s, CH), 6.54  (s, CH), 4.20  (d, CH2), 3.07  (d, CH2), 8.1  (s, NH), 8.60 
(s, N=CH), 7.2  (s, CH), 7.2  (s, CH), 7.7  (s, CH), 8.15  (s, CH), 6.34  (s, H); MS: m/z 575.4 
11 
IR: 3460, 3361, 3221, 3041, 2993, 1658 for CO of CONH, 1625, 1589, 1490, 1448, 1317, 1226, 964, 869, 771, 678 cm−1;
1H NMR  (400 MHz, DMSO-d6): δ 3.72  (t, CH3), 6.40  (s, CH), 3.25  (d, CH2), 6.51  (s, CH), 6.54  (s, CH), 4.25  (d, CH2), 
3.07  (d, CH2), 8.2  (s, NH), 8.8  (s, N=CH), 3.0  (s, CH), 6.87  (s, CH), 6.57  (s, CH), 6.83  (s, CH), 4.0  (d NH2), 6.33  (s, H); 
MS: m/z 367.3 
18 
IR: 3431, 3211, 3045, 3016, 1653 for CO of CONH, 1573, 1504, 1467, 1292, 1251, 1157, 1056, 819, 682, 516 cm−1; 1H NMR
(400 MHz, DMSO-d6): δ 3.75  (t, CH3), 6.40  (s, CH), 3.22  (d, CH2), 6.51  (s, CH), 6.54  (s, CH), 4.18  (d, CH2), 3.07  (d, 
CH2), 8.1  (s, NH), 8.6  (s, N=CH), 7.4  (s, CH), 6.8  (s, CH), 7.1  (s, CH), 6.8  (s, CH), 5.0  (s, OH), 6.33  (s, H); MS: m/z 339.1 
30 
IR: 3460, 3361, 3221, 1658 for CO of CONH, 1625, 1589, 1448, 1317, 1282, 1226, 869, 771, 678, 576 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 3.71 (t, CH3), 6.40 (s, CH), 3.25 (d, CH2), 6.51 (s, CH), 6.54 (s, CH), 4.24 (d, CH2), 3.07 (d, CH2),8.1 
(s,NH), 8.6 (s, N=CH), 3.0 (s, CH), 1.2 (t, CH3) 6.48 (s, CH), 6.96 (s, CH), 6.28 (s, CH), 4.0 (d NH2), 6.34 (s, H); MS: m/z
366.3 
34 
IR: 3419, 3223, 3089, 2900, 2806, 1651 for CO of CONH, 1570, 1502, 1371, 1055, 815, 675, 514 cm−1. 1H NMR  (400 MHz, 
DMSO-d6): δ 3.73 (t, CH3), 6.40 (s, CH), 3.20 (d, CH2), 6.51 (s, CH), 6.54 (s, CH), 4.24 (d, CH2), 3.07 (d, CH2) 8.1 (s,NH), 8.6 
(s, N=CH), 3.0 (s, CH), 1.2 (t, CH3), 6.68 (s, CH), 7.04 (s, CH), 6.55 (s, CH), 5.2 (s, OH), 6.33 (s, H); MS: m/z 367.2 
35 
IR: 3089, 1680 for CO of CONH, 1608, 1519, 1419, 1342, 1242, 1101, 968, 910, 665, 582, 534 cm−1; 1H NMR (400 MHz, 
DMSO-d6): δ 3.75 (t, CH3), 6.40 (s, CH), 3.20 (d, CH2), 6.51 (s, CH), 6.54 (s, CH), 4.24 (d, CH2), 3.07 (d, CH2),8.1 (s,NH), 8.6 
(s, N=CH), 3.0 (s, CH), 1.2 (t, CH3), 7.51 (s, CH), 7.47 (s, CH), 8.01 (s, CH), 6.34 (s, H); MS: m/z 396.2 
37 
IR: 3288, 3251, 3180, 3109, 1660 for CO of CONH, 1589, 1523, 1475, 815, 732 cm−1; 1H NMR  (400 MHz, DMSO-d6): δ 3.74 
(t, CH3), 6.40 (s, CH), 3.22 (d, CH2), 6.51 (s, CH), 6.54 (s, CH), 4.23 (d, CH2), 3.07 (d, CH2),8.1 (s,NH), 8.6 (s, N=CH), 3.0 (s,
CH), 1.2 (t, CH3) 6.87 (s, CH), 6.41 (s, CH), 6.41 (s, CH), 4.2 (d NH2), 6.32 (s, H); MS: m/z 366.1 
42 
IR: 3288, 2945, 1653 for CO of CONH, 1568, 1506, 1352, 1273, 1213, 1157, 1066, 840, 665, 561 cm−1; 1H NMR  (400 MHz, 
DMSO-d6): δ 3.73 (t, CH3), 6.40 (s, CH), 3.22 (d, CH2), 6.51 (s, CH), 6.54 (s, CH), 4.24 (d, CH2), 3.07 (d, CH2),8.1 (s, NH), 8.6 
(s, N=CH), 3.0 (s, CH), 1.2 (t, CH3), 6.78 (s, CH), 6.95 (s, CH), 6.68 (s, CH), 5.0 (s, OH), 6.34 (s, H); MS: m/z 366.8 
45 
IR: 3192, 3018, 2837, 1680 for CO of CONH, 1556, 1278, 1145, 1055, 810, 673, 514 cm−1; 1H NMR  (400 MHz, DMSO-d6): δ 
3.73  (t, CH3), 6.40  (s, CH), 3.22  (d, CH2), 6.51  (s, CH), 6.54  (s, CH), 4.23  (d, CH2), 3.07  (d, CH2), 8.1  (s,NH), 8.6  (s, 
N=CH), 3.0  (s, CH), 1.2  (t, CH3), 7.12  (s, CH), 7.21  (s, CH), 7.08  (s, CH), 6.34  (s, H); MS: m/z 351.2 
 
Table V — Antimycobacterial activity of compounds 
Sr.No Sample 100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
12.5 
µg/mL 
6.25 
µg/mL 
3.12 
µg/mL 
1.6 
µg/mL 
0.8 
µg/mL 
1 4 S S R R R R R R 
2 5 S S R R R R R R 
3 11 S S S R R R R R 
4 18 S S R R R R R R 
5 30 S R R R R R R R 
6 34 S S R R R R R R 
7 35 S S R R R R R R 
8 37 S S R R R R R R 
9 42 S S R R R R R R 
10 45 S S R R R R R R 
11 Isoniazide S S S S R R R R 
NOTE: S - Sensitive R- Resistant 
 
ROHANE & CHAUHAN: NOVEL HYDRAZONE DERIVATIVES 
 
 
709
method, with Isoniazide as the reference standard. 
The results expressed in minimum inhibitory 
concentration (MIC) are listed in Table V and the 
colour change observed during assay method is shown 
in Figure 2. The obtained results indicate the 
biological potential and varying activity depending  
on the type of substituent on hydrazidenucleus. The 
most promising seems to be compound no. 11  
which show the sensitivity towards bacteria at  
25 µg/mL level.  
 
Conclusions 
Several new hydrazone derivatives bearing 
aromatic aldehyde or ketone by there action of 
aryloxyhydrazide with appropriate aldehyde or ketone 
or substitutes derivatives of both. The structures of 
obtained compounds were confirmed by spectroscopic 
methods. All newly obtained hydrazone derivatives 
were tested in vitro against Mycobacterium strains: 
M. H37Rv. The antibacterial activity is strongly 
connected with the position of the substituent on 
aromatic aldehyde or ketones in relation to the 
hydrazide skeleton. All synthesized compounds found 
to be most active against Mycobacterium tuberculosis. 
The molecular docking studies investigating 
hydrazone derivatives using the enzyme 2NSD and 
2X22 as their potential biological target indicated that 
the amino, azide, hydroxyl and phenyl nucleus of 
hydrazone derivatives spacer play an important role in 
interactions with the active site such as TYR 158, ILE 
215, GLU 219, PHE 97 and PHE 149 as the most 
active amino acid residues. 
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Figure 2 — Microplate Alamar Blue assay (MABA) colour change 
 
